Browsing Tag
Boston Scientific Corporation
4 posts
Emboline clears FDA as Emboliner takes full-body protection into U.S. TAVR market
Emboline has secured FDA 510(k) clearance for Emboliner, opening U.S. sales of a TAVR protection system designed to capture debris heading toward both the brain and other organs.
Heart ablation is moving beyond heat and cold, and the medtech race is getting much bigger
Pulsed field ablation is changing atrial fibrillation treatment by using extremely short electrical pulses to disrupt targeted cardiac cells instead of relying primarily on heat or freezing. Boston Scientific, Medtronic, Abbott Laboratories and Johnson & Johnson now compete across multiple FDA-approved PFA platforms, while new trials are pushing the technology into persistent atrial fibrillation, broader lesion sets and potentially earlier treatment.
Saluda Medical wins CAP24 FDA approval as ASX:SLD shares rally 22%
Discover how Saluda Medical’s CAP24 FDA approval may expand Evoke adoption, reshape SCS competition and test ASX’s execution. Read the analysis in full.
Abbott (NYSE: ABT) showcases four HRS 2026 trials as cardiac rhythm market competition intensifies
Abbott has fresh arrhythmia data, but its stock sits near yearly lows. Can cardiac innovation reset investor confidence?